Practice and development of male contraception: European Academy of Andrology and American Society of Andrology guidelines.
barrier methods
behaviors
contraceptive efficacy
couple-centerd communication
guidelines
hormonal methods
male contraception
non-hormonal methods
physical agents
semen analysis
social and ethical considerations
surgical methods
vaccines
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
20 Sep 2023
20 Sep 2023
Historique:
received:
30
08
2023
accepted:
31
08
2023
medline:
20
9
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
aheadofprint
Résumé
Despite a wide spectrum of contraceptive methods for women, the unintended pregnancy rate remains high (45% in the US), with 50% resulting in abortion. Currently, 20% of global contraceptive use is male-directed, with a wide variation among countries due to limited availability and lack of efficacy. Worldwide studies indicate that >50% of men would opt to use a reversible method, and 90% of women would rely on their partner to use a contraceptive. Additional reasons for novel male contraceptive methods to be available include the increased life expectancy, sharing the reproductive risks among partners, social issues, the lack of pharma industry involvement and the lack of opinion makers advocating for male contraception. The present guidelines aim to review the status regarding male contraception, the current state of the art to support the clinical practice, recommend minimal requirements for new male contraceptive development and provide and grade updated, evidence-based recommendations from the European Society of Andrology (EAA) and the American Society of Andrology (ASA). An expert panel of academicians appointed by the EAA and the ASA generated a consensus guideline according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system. Sixty evidence-based and graded recommendations were produced on couple-centered communication, behaviors, barrier methods, semen analysis and contraceptive efficacy, physical agents, surgical methods, actions before initiating male contraception, hormonal methods, non-hormonal methods, vaccines, and social and ethical considerations. As gender roles transform and gender equity is established in relationships, the male contribution to family planning must be facilitated. Efficient and safe male-directed methods must be evaluated and introduced into clinical practice, preferably reversible, either hormonal or non-hormonal. From a future perspective, identifying new hormonal combinations, suitable testicular targets, and emerging vas occlusion methods will produce novel molecules and products for male contraception.
Sections du résumé
BACKGROUNDS
BACKGROUND
Despite a wide spectrum of contraceptive methods for women, the unintended pregnancy rate remains high (45% in the US), with 50% resulting in abortion. Currently, 20% of global contraceptive use is male-directed, with a wide variation among countries due to limited availability and lack of efficacy. Worldwide studies indicate that >50% of men would opt to use a reversible method, and 90% of women would rely on their partner to use a contraceptive. Additional reasons for novel male contraceptive methods to be available include the increased life expectancy, sharing the reproductive risks among partners, social issues, the lack of pharma industry involvement and the lack of opinion makers advocating for male contraception.
AIM
OBJECTIVE
The present guidelines aim to review the status regarding male contraception, the current state of the art to support the clinical practice, recommend minimal requirements for new male contraceptive development and provide and grade updated, evidence-based recommendations from the European Society of Andrology (EAA) and the American Society of Andrology (ASA).
METHODS
METHODS
An expert panel of academicians appointed by the EAA and the ASA generated a consensus guideline according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system.
RESULTS
RESULTS
Sixty evidence-based and graded recommendations were produced on couple-centered communication, behaviors, barrier methods, semen analysis and contraceptive efficacy, physical agents, surgical methods, actions before initiating male contraception, hormonal methods, non-hormonal methods, vaccines, and social and ethical considerations.
CONCLUSION
CONCLUSIONS
As gender roles transform and gender equity is established in relationships, the male contribution to family planning must be facilitated. Efficient and safe male-directed methods must be evaluated and introduced into clinical practice, preferably reversible, either hormonal or non-hormonal. From a future perspective, identifying new hormonal combinations, suitable testicular targets, and emerging vas occlusion methods will produce novel molecules and products for male contraception.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 American Society of Andrology and European Academy of Andrology.
Références
Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med. 2016;374(9):843-852.
Sundaram A, Vaughan B, Kost K, et al. Contraceptive failure in the United States: estimates from the 2006-2010 National Survey of Family Growth. Perspect Sex Reprod Health. 2017;49(1):7-16.
Contraceptive use in the United States by method [Internet]. Guttmacher Institute; 2018. https://www.guttmacher.org/fact-sheet/contraceptive-method-use-united-states
Ross J, Hardee K. Use of male methods of contraception worldwide. J Biosoc Sci. 2017;49(5):648-663.
Heinemann K, Saad F, Wiesemes M, White S, Heinemann L. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod Oxf Engl. 2005;20(2):549-556.
Glasier A. Acceptability of contraception for men: a review. Contraception. 2010;82(5):453-456.
Nieschlag E, Nieschlag S. Why we need more methods for male contraception. Andrology. 2023;11(3):421-424.
Wang C, Swerdloff RS, Approaches to contraceptive methods for men. Oxf Res Encycl Glob Public Health [Internet]. October 19, 2022. https://oxfordre.com/publichealth/view/10.1093/acrefore/9780190632366.001.0001/acrefore-9780190632366-e-371
Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93(3):666-673.
Informed consent and shared decision making in obstetrics and gynecology: aCOG Committee Opinion, Number 819. Obstet Gynecol. 2021;137(2):e34-e41.
American College of Obstetricians and Gynecologists’ Committee on Health Care for Underserved Women, Contraceptive Equity Expert Work Group, and Committee on Ethics. Patient-Centered Contraceptive Counseling: aCOG Committee Statement Number 1. Obstet Gynecol. 2022;139(2):350-353.
Hall KS, Castaño PM, Westhoff CL. The influence of oral contraceptive knowledge on oral contraceptive continuation among young women. J Womens Health 2002. 2014;23(7):596-601.
Moore PJ, Adler NE, Kegeles SM. Adolescents and the contraceptive pill: the impact of beliefs on intentions and use. Obstet Gynecol. 1996;88(3):48S-56S.
Birth control [Internet]. [cited May 28, 2023]. https://www.acog.org/en/womens-health/faqs/birth-control
Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(3):1-103.
Teal S, Edelman A. Contraception selection, effectiveness, and adverse effects: a review. JAMA. 2021;326(24):2507.
Dude A, Neustadt A, Martins S, Gilliam M. Use of withdrawal and unintended pregnancy among females 15-24 years of age. Obstet Gynecol. 2013;122(3):595-600.
Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404.
Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23. 2010(29):1-44.
Managing contraception [Internet]. [cited May 29, 2023]. Contraceptive Technology 21st ed. https://managingcontraception.com/contraceptive-technology-21st-edition/
Jennings VH, Landy H. Explaining ovulation awareness-based family planning methods. Contemp ObGyn. 2006:51.
Arévalo M, Jennings V, Sinai I. Efficacy of a new method of family planning: the Standard Days Method. Contraception. 2002;65(5):333-338.
Arévalo M, Jennings V, Nikula M, Sinai I. Efficacy of the new TwoDay Method of family planning. Fertil Steril. 2004;82(4):885-892.
Frank-Herrmann P, Heil J, Gnoth C, et al. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple's sexual behaviour during the fertile time: a prospective longitudinal study. Hum Reprod Oxf Engl. 2007;22(5):1310-1319.
Trussell J, Grummer-Strawn L. Contraceptive failure of the ovulation method of periodic abstinence. Fam Plann Perspect. 1990;22(2):65-75.
Knight J. The Complete Guide to Fertility Awareness. Routledge; 2017.
Horan PF, Phillips J, Hagan NE. The meaning of abstinence for college students. J HIVAIDS Prev Educ Adolesc Child. 1998;2(2):51-66.
Polls CB, Bradley SEK, Bankole A, Akinrinola TO, Croft TN, Singh S, Contraceptive failure rates in the developing world: an analysis of demographic and health survey data in 43 countries [Internet]. Guttmacher Institute; 2016. https://www.guttmacher.org/sites/default/files/report_pdf/contraceptive-failure-rates-in-developing-world_1.pdf
Irfan M, Hussain NHN, Noor NM, Mohamed M, Ismail SB. Sexual abstinence and associated factors among young and middle-aged men: a systematic review. J Sex Med. 2020;17(3):412-430.
United Nations Department of Economic and Social Affairs Population Division. Contracpetiv use by methods. United Nations; 2019.
Copen CE. Condom use during sexual intercourse among women and men aged 15-44 in the United States: 2011-2015 National Survey of Family Growth. Natl Health Stat Rep. 2017;105(105):1-18.
Trussell J AA Micks E, Guthrie KA. Efficacy, safety, and personal considerations. In: Hatcher RA NA Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken ARA, Marrazzo J, Kowal D, eds. Contraceptive Technology. 21st ed.. Ayer Company Publishers, Inc.; 2018.
Lam JU, Rebolj M, Dugué PA, Bonde J, von Euler-Chelpin M, Lynge E. Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen. 2014;21(1):38-50.
Whiting W, Pharr JR, Buttner MP, Lough NL. Behavioral interventions to increase condom use among college students in the United States: a systematic review. Health Educ Behav. 2019;46(5):877-888.
Gallo MF, Grimes DA, Lopez LM, Schulz KF. Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev. 2006;1(1):Cd003550.
Evans WD, Ulasevich A, Hatheway M, Deperthes B. Systematic review of peer-reviewed literature on global condom promotion programs. Int J Env Res Public Health [Internet]. 2020;17(7). https://mdpi-res.com/d_attachment/ijerph/ijerph-17-02262/article_deploy/ijerph-17-02262-v2.pdf?version=1586223080
World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. Sixth. WHO; 2021.
Lemmens L, van den Hoven L, van Vrouwerff NJ, et al. External quality control and training of semen analysis in the Netherlands: starting point for further reduction of outcome variability. Asian J Androl. 2022;24(1):15-20.
Nieschlag E, Pock T, Hellenkemper B. External quality of semen analysis reveals low compliance with the WHO guidelines. J Reproduktionsmed EndokrinolOnline. 2017;14(6):306-310.
Behre HM, Zitzmann M, Anderson RA, et al. Efficacy and safety of an injectable combination hormonal contraceptive for men. J Clin Endocrinol Metab. 2016;101(12):4779-4788.
Trussell J, Portman D. The creeping Pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills? Contraception. 2013;88(5):604-610.
Garolla A, Torino M, Sartini B, et al. Seminal and molecular evidence that sauna exposure affects human spermatogenesis. Hum Reprod. 2013;28(4):877-885.
Lue Y, Hikim AP, Wang C, Im M, Leung A, Swerdloff RS. Testicular heat exposure enhances the suppression of spermatogenesis by testosterone in rats: the “two-hit” approach to male contraceptive development. Endocrinology. 2000;141(4):1414-1424.
Lue Y, Wang C, Liu YX, et al. Transient testicular warming enhances the suppressive effect of testosterone on spermatogenesis in adult cynomolgus monkeys (Macaca fascicularis). J Clin Endocrinol Metab. 2006;91(2):539-545.
Wang C, Cui YG, Wang XH, et al. Transient scrotal hyperthermia and levonorgestrel enhance testosterone-induced spermatogenesis suppression in men through increased germ cell apoptosis. J Clin Endocrinol Metab. 2007;92(8):3292-3304.
Mieusset R, Grandjean H, Mansat A, Pontonnier F. Inhibiting effect of artificial cryptorchidism on spermatogenesis. Ferti Steril. 1985;43(4):589-594.
Mieusset R, Bujan L. The potential of mild testicular heating as a safe, effective and reversible contraceptive method for men. J Androl. 1994;17(4):186-191.
Abdelhamid MHM, Esquerre-Lamare C, Walschaerts M, et al. Experimental mild increase in testicular temperature has drastic, but reversible, effect on sperm aneuploidy in men: a pilot study. Reprod Biol. 2019;19(2):189-194.
Srivasatav S, Mishra J, Keshari P, Verma S, Aditi R. Impact of radiation on male fertility. Adv Exp Med Biol. 2022;1391:71-82.
Sharlip ID, Belker AM, Honig S, et al. Vasectomy: AUA guideline. J Urol. 2012;188(6):2482-2491.
Zini A, Grantmyre J, Chow V, Chan P. UPDATE - 2022 Canadian Urological Association best practice report: vasectomy. Can Urol Assoc J. 2022;16(5):E231-E236.
Hancock P, Woodward BJ, Muneer A, Kirkman-Brown JC. 2016 Laboratory guidelines for postvasectomy semen analysis: association of Biomedical Andrologists, the British Andrology Society and the British Association of Urological Surgeons. J Clin Pathol. 2016;69(7):655-660.
Dohle GR, Diemer T, Kopa Z, et al. European Association of Urology guidelines on vasectomy. Eur Urol. 2012;61(1):159-163.
Hupertan V, Graziana JP, Schoentgen N, et al. [Recommendations of the Committee of Andrology and Sexual Medicine of the AFU concerning the management of Vasectomy]. Prog Urol. 2023;33(5):223-236.
Tomlinson M, Pooley K, Kohut T, Atkinson M. Is azoospermia the appropriate standard for post-vasectomy semen analysis? Or an unachievable goal of best practice laboratory guidelines. Hum Fertil Camb Engl. 2020;23(4):268-274.
McMartin C, Lehouillier P, Cloutier J, Singbo N, Labrecque M. Can a low sperm concentration without assessing motility confirm vasectomy success? A retrospective descriptive study. J Urol. 2021;206(1):109-114.
Atkinson M, James G, Bond K, Harcombe Z, Labrecque M. Comparison of postal and non-postal post-vasectomy semen sample submission strategies on compliance and failures: an 11-year analysis of the audit database of the Association of Surgeons in Primary Care of the UK. BMJ Sex Reprod Health. 2022;48(1):54-59.
Trussler J, Browne B, Merino M, Kuftinec D, McCullough A. Post-vasectomy semen analysis compliance with use of a home-based test. Can J Urol. 2020;27(5):10388-10393.
Bradshaw A, Ballon-Landa E, Owusu R, Hsieh TC. Poor compliance with postvasectomy semen testing: analysis of factors and barriers. Urology. 2020;136:146-151.
Duplisea J, Whelan T. Compliance with semen analysis. J Urol. 2013;189(6):2248-2251.
Belker AM, Sexter MS, Sweitzer SJ, Raff MJ. The high rate of noncompliance for post-vasectomy semen examination: medical and legal considerations. J Urol. 1990;144(2):284-286. Pt 1.
Jacobsen FM, Jensen CFS, Fode M, Sønksen J, Ohl DA, CopMich Collaborative. Scheduling appointments for postvasectomy semen analysis has no impact on compliance. Eur Urol Open Sci. 2020;22:74-78.
Dhar NB, Jones JS, Bhatt A, Babineau D. A prospective evaluation of the impact of scheduled follow-up appointments with compliance rates after vasectomy. BJU Int. 2007;99(5):1094-1097.
Doolittle J, Jackson EM, Gill B, Vij SC. The omission of genitourinary physical exam in telehealth pre-vasectomy consults does not reduce rates of office procedure completion. Urology. 2022;167:19-23.
Kampire HT, Cloutier J, Dallaire M, Plourde S, Labrecque M. Men prefer pre-vasectomy consultation by telephone: a survey of vasectomized men. Can J Urol. 2022;29(5):11307-11311.
Guha SK, Singh G, Ansari S, et al. Phase II clinical trial of a vas deferens injectable contraceptive for the male. Contraception. 1997;56(4):245-250.
Guha SK, Singh G, Anand S, Ansari S, Kumar S, Koul V. Phase I clinical trial of an injectable contraceptive for the male. Contraception. 1993;48(4):367-375.
Sharma RS, Mathur AK, Singh R, et al. Safety & efficacy of an intravasal, one-time injectable & non-hormonal male contraceptive (RISUG): a clinical experience. Indian J Med Res. 2019;150(1):81-86.
Doolittle J, Kansal J, Dietrich P, et al. Is opioid-free post-vasectomy analgesia a pain? A single surgeon experience. Urology. 2021;154:40-44.
Baker BH, Fox JA, Womble PR, Stromberg IH, Grossgold ET, Walters RC. Optimizing opioid pain medication use after vasectomy-a prospective study. Urology. 2020;136:41-45.
Nam CS, Lai YL, Hu HM, et al. Less is more: fulfillment of opioid prescriptions before and after implementation of a modifier 22 based quality incentive for opioid-free vasectomies. Urology. 2023;171:103-108.
Welk B, McClure JA, Clarke C, Vogt K, Campbell J. An opioid prescription for men undergoing minor urologic surgery is associated with an increased risk of new persistent opioid use. Eur Urol. 2020;77(1):68-75.
Barham DW, McMann LP, Musser JE, et al. Routine prescription of opioids for post-vasectomy pain control associated with persistent use. J Urol. 2019;202(4):806-810.
Guha SK. Biophysical mechanism-mediated time-dependent effect on sperm of human and monkey vas implanted polyelectrolyte contraceptive. Asian J Androl. 2007;9(2):221-227.
Ansari AS, Badar A, Balasubramanian K, Lohiya NK. Contraception with RISUG® and functional reversal through DMSO and NaHCO3 in male rabbits. Asian J Androl. 2017;19(4):389-395.
Zhao SC, Zhang SP, Yu RC. Intravasal injection of formed-in-place silicone rubber as a method of vas occlusion. Int J Androl. 1992;15(6):460-464.
Soebadi DM, Gardjito W, Mensink HJ. Intravasal injection of formed-in-place medical grade silicone rubber for vas occlusion. Int J Androl. 1995;18:45-52. Suppl 1.
Zhao SC. Vas deferens occlusion by percutaneous injection of polyurethane elastomer plugs: clinical experience and reversibility. Contraception. 1990;41(5):453-459.
Zambon JV, Barone MA, Pollack AE, Mehta M. Efficacy of percutaneous vas occlusion compared with conventional vasectomy. BJU Int. 2000;86(6):699-705. discussion 705-706.
Lu WH, Liang XW, Gu YQ, et al. A randomized, controlled, multicenter contraceptive efficacy clinical trial of the intravas device, a nonocclusive surgical male sterilization. Asian J Androl. 2014;16(3):432-436.
Song L, Gu Y, Lu W, Liang X, Chen Z. A phase II randomized controlled trial of a novel male contraception, an intra-vas device. Int J Androl. 2006;29(4):489-495.
Waller D, Bolick D, Lissner E, Premanandan C, Gamerman G. Reversibility of Vasalgel™ male contraceptive in a rabbit model. Basic Clin Androl. 2017;27:8.
Wang ZQ, Liu ZQ, Zhao CH, et al. An ultrasound-induced self-clearance hydrogel for male reversible contraception. ACS Nano. 2022;16(4):5515-5528.
Andreoletti M, Bina F. A defense of surgical procedures regulation. Theor Med Bioeth. 2022;43(2-3):155-168.
Amory JK. Development of novel male contraceptives. Clin Transl Sci. 2020;13(2):228-237.
Long JE, Lee MS, Blithe DL. Update on novel hormonal and nonhormonal male contraceptive development. J Clin Endocrinol Metab. 2021;106(6):e2381-e2392.
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432.
Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: european Society of Endocrinology. Andrology. 2020;8(5):970-987.
Giagulli VA, Castellana M, Lisco G, Triggiani V. Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology. 2020;8(6):1628-1641.
Salonia A, Bettocchi C, Boeri L, et al. European Association of Urology Guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol. 2021;80(3):333-357.
Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117.
Zöller B, Svensson PJ, Dahlbäck B, Lind-Hallden C, Hallden C, Elf J. Genetic risk factors for venous thromboembolism. Expert Rev Hematol. 2020;13(9):971-981.
Committee A. ACOG Committee Opinion No. 754: the utility of and indications for routine pelvic examination. Obstet Gynecol. 2018;132(4):e174-e180.
Wang C, Festin MP, Swerdloff RS. Male hormonal contraception: where are we now? Curr Obstet Gynecol Rep. 2016;5:38-47.
Walker RF, Zakai NA, MacLehose RF, et al. Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism. JAMA Intern Med. 2020;180(2):190-197.
White WB, Dobs A, Carson C, et al. Effects of a novel oral testosterone undecanoate on ambulatory blood pressure in hypogonadal men. J Cardiovasc Pharmacol Ther. 2021;26(6):630-637.
Honig S, Gittelman M, Kaminetsky J, et al. Two-year analysis of a new oral testosterone undecanoate (TU) formulation in hypogonadal men: efficacy, impact on psychosexual function, and safety. J Sex Med. 2022;19(12):1750-1758.
Gittelman M, Jaffe JS, Kaminetsky JC. Safety of a new subcutaneous testosterone enanthate auto-injector: results of a 26-week study. J Sex Med. 2019;16(11):1741-1748.
Qin J, Saraiya M, Martinez G, Sawaya GF. Prevalence of potentially unnecessary bimanual pelvic examinations and papanicolaou tests among adolescent girls and young women aged 15-20 years in the United States. JAMA Intern Med. 2020;180(2):274-280.
Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367(9520):1412-1420.
Piotrowska K, Wang C, Swerdloff RS, Liu PY. Male hormonal contraception: hope and promise. Lancet Diabetes Endocrinol. 2017;5(3):214-223.
Nieschlag E, Vorona E, Wenk M, Hemker AK, Kamischke A, Zitzmann M. Hormonal male contraception in men with normal and subnormal semen parameters. Int J Androl. 2011;34(6):556-567.
Warren AM, Grossmann M. Haematological actions of androgens. Best Pr Res Clin Endocrinol Metab. 2022;36(5):101653.
Gui YL, He CH, Amory JK, et al. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men. J Androl. 2004;25(5):720-727.
Ilani N, Roth MY, Amory JK, et al. A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. J Clin Endocrinol Metab. 2012;97(10):3476-3486.
Smith LB, Walker WH. The regulation of spermatogenesis by androgens. Semin Cell Dev Biol. 2014;30:2-13.
McLachlan RI, O'Donnell L, Meachem SJ, et al. Hormonal regulation of spermatogenesis in primates and man: insights for development of the male hormonal contraceptive. J Androl. 2002;23(2):149-162.
Aaltonen P, Amory JK, Anderson RA, et al. 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. J Androl. 2007;28(3):362-363.
Gonzalo IT, Swerdloff RS, Nelson AL, et al. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002;87(8):3562-3572.
Kamischke A, Heuermann T, Krüger K, et al. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab. 2002;87(2):530-539.
Patanelli D. Hormonal Control of Male Fertility. Department of Health, Education, and Welfare; 1978:145-172. (DHEW Publication No. NIH 78-1097); 1978.
World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990;336(8721):955-959.
Gu YQ, Wang XH, Xu D, et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab. 2003;88(2):562-568.
Gu Y, Liang X, Wu W, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab. 2009;94(6):1910-1915. 2009/03/19 ed.
World Health Organization Task Force on the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65(4):821-829.
Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Ferti Steril. 1996;65(3):626-636.
Eberhardt J, van Wersch A, Meikle N. Attitudes towards the male contraceptive pill in men and women in casual and stable sexual relationships. J Fam Plann Reprod Health Care. 2009;35(3):161-165.
Brooks M. Men's views on male hormonal contraception-a survey of the views of attenders at a fitness centre in Bristol, UK. Br J Fam Plann. 1998;24(1):7-17.
Thirumalai A, Ceponis J, Amory JK, et al. Effects of 28 days of oral dimethandrolone undecanoate in healthy men: a prototype male pill. J Clin Endocrinol Metab. 2019;104(2):423-432.
Yuen F, Thirumalai A, Pham C, et al. Daily oral administration of the novel androgen 11β-MNTDC markedly suppresses serum gonadotropins in healthy men. J Clin Endocrinol Metab. 2020;105(3):e835-e847.
Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology. 2006;147(6):3016-3026.
Attardi BJ, Hild SA, Koduri S, et al. The potent synthetic androgens, dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone, do not require 5alpha-reduction to exert their maximal androgenic effects. J Steroid Biochem Mol Biol. 2010;122(4):212-218.
von Eckardstein S, Noe G, Brache V, et al. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab. 2003;88(11):5232-5239.
Zhang L, Shah IH, Liu Y, Vogelsong KM. The acceptability of an injectable, once-a-month male contraceptive in China. Contraception. 2006;73(5):548-553.
Meriggiola MC, Costantino A, Cerpolini S, et al. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. J Clin Endocrinol Metab. 2003;88(12):5818-5826.
Liu PY, Swerdloff RS, Anawalt BD, et al. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab. 2008;93(5):1774-1783.
Meriggiola MC, Farley TM, Mbizvo MT. A review of androgen-progestin regimens for male contraception. J Androl. 2003;24(4):466-483.
Wang C, Swerdloff RS. Male hormonal contraception. Am J Obstet Gynecol. 2004;190(4):S60-S68.
Lue Y, Wang C, Lydon JP, Leung A, Li J, Swerdloff RS. Functional role of progestin and the progesterone receptor in the suppression of spermatogenesis in rodents. Andrology. 2013;1(2):308-317.
Turner L, Conway AJ, Jimenez M, et al. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab. 2003;88(10):4659-4667.
Soufir JC, Meduri G, Ziyyat A. Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod. 2011;26(7):1708-1714.
Meriggiola MC, Costantino A, Saad F, et al. Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab. 2005;90(4):2005-2014.
Kamischke A, Venherm S, Ploger D, von Eckardstein S, Nieschlag E. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab. 2001;86(1):303-309.
Anawalt BD, Roth MY, Ceponis J, et al. Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men. Andrology. 2019;7(6):878-8787.
Mahabadi V, Amory JK, Swerdloff RS, et al. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J Clin Endocrinol Metab. 2009;94(7):2313-2320.
Yuen F, Wu S, Thirumalai A, et al. Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel. Andrology. 2019;7(2):235-243.
Amory JK, Blithe DL, Sitruk-Ware R, et al. Design of an international male contraceptive efficacy trial using a self-administered daily transdermal gel containing testosterone and segesterone acetate (Nestorone). Contraception. 2023;124:110064.
Anawalt BD, Amory JK, Herbst KL, et al. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. J Androl. 2005;26(3):405-413.
Meriggiola MC, Bremner WJ, Costantino A, Pavani A, Capelli M, Flamigni C. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Ferti Steril. 1997;68(5):844-850.
Mommers E, Kersemaekers WM, Elliesen J, et al. Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2008;93(7):2572-2580.
Meriggiola MC, Cerpolini S, Bremner WJ, et al. Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men. Hum Reprod Oxf Engl. 2006;21(8):2033-2040.
Nieschlag E, Behre HM. Testosterone: Acion, Deficiency, Substitution. Vol. Third. Cambridge University Pressm; 2004.
Swerdloff RS, Bagatell CJ, Wang C, et al. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab. 1998;83(10):3527-3533.
Behre HM, Kliesch S, Lemcke B, von Eckardstein S, Nieschlag E. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod. 2001;16(12):2570-2577.
Page ST, Amory JK, Anawalt BD, et al. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab. 2006;91(11):4374-4380.
Campbell MJ, Lotti F, Baldi E, et al. Distribution of semen examination results 2020 - A follow up of data collated for the WHO semen analysis manual 2010. Andrology. 2021;9(3):817-822.
Waites GM, Wang C, Griffin PD. Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. Int J Androl. 1998;21(1):8-12.
Qian SZ. Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. Contraception. 1987;36(3):335-345.
Thirumalai A, Amory JK. Emerging approaches to male contraception. Fertil Steril. 2021;115(6):1369-1376.
Indrawati I Widyowati R, Kopeuw P, Wardoyo BEP. Ethnomedicine Study on Justicia gendarussa for male contraception at the Nimboran Ethnic. Jayapura J Farm Dan Ilmu Kefarmasian Indones. 2022;9:55-61.
Amory JK, Muller CH, Page ST, et al. Miglustat has no apparent effect on spermatogenesis in normal men. Hum Reprod. 2007;22(3):702-707.
Cheng CY, Mo M, Grima J, et al. Indazole carboxylic acids in male contraception. Contraception. 2002;65(4):265-268.
O'Rand MG, Silva EJ, Hamil KG. Non-hormonal male contraception: a review and development of an Eppin based contraceptive. Pharmacol Ther. 2016;157:105-111.
Noman MAA, Kyzer JL, Chung SSW, Wolgemuth DJ, Georg GI. Retinoic acid receptor antagonists for male contraception: current status†. Biol Reprod. 2020;103(2):390-399.
Paik J, Haenisch M, Muller CH, et al. Inhibition of retinoic acid biosynthesis by the bisdichloroacetyldiamine WIN 18,446 markedly suppresses spermatogenesis and alters retinoid metabolism in mice. J Biol Chem. 2014;289(21):15104-15117.
Matzuk MM, McKeown MR, Filippakopoulos P, et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012;150(4):673-684.
Yu Z, Ku AF, Anglin JL, et al. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT. Proc Natl Acad Sci USA. 2021;118(9):e2021102118.
Lishko PV, Kirichok Y. The role of Hv1 and CatSper channels in sperm activation: hv1 and CatSper channels in sperm activation. J Physiol. 2010;588(23):4667-46672.
Carlson AE, Westenbroek RE, Quill T, et al. CatSper1 required for evoked Ca 2+ entry and control of flagellar function in sperm. Proc Natl Acad Sci USA. 2003;100(25):14864-14868.
Avenarius MR, Hildebrand MS, Zhang Y, et al. Human male infertility caused by mutations in the CATSPER1 channel protein. Am J Hum Genet. 2009;84(4):505-510.
Schreiber M, Wei A, Yuan A, Gaut J, Saito M, Salkoff L. Slo3, a novel pH-sensitive K+ channel from mammalian spermatocytes. J Biol Chem. 1998;273(6):3509-3516.
Navarro B, Kirichok Y, Clapham DE. KSper, a pH-sensitive K + current that controls sperm membrane potential. Proc Natl Acad Sci USA. 2007;104(18):7688-7692.
Santi CM, Martínez-López P, De La, Vega-Beltrán JL, et al. The SLO3 sperm-specific potassium channel plays a vital role in male fertility. FEBS Lett. 2010;584(5):1041-1046.
Lyon M, Li P, Ferreira JJ, et al. A selective inhibitor of the sperm-specific potassium channel SLO3 impairs human sperm function. Proc Natl Acad Sci USA. 2023;120(4):e2212338120.
Liu R, Yan Z, Fan Y, et al. Bi-allelic variants in KCNU1 cause impaired acrosome reactions and male infertility. Hum Reprod. 2022;37(7):1394-1405.
Balbach M, Rossetti T, Ferreira J, et al. On-demand male contraception via acute inhibition of soluble adenylyl cyclase. Nat Commun. 2023;14(1):637.
Salicioni AM, Gervasi MG, Sosnik J, et al. Testis-specific serine kinase protein family in male fertility and as targets for non-hormonal male contraception†. Biol Reprod. 2020;103(2):264-274.
Chang Z, Qin W, Zheng H, et al. Triptonide is a reversible non-hormonal male contraceptive agent in mice and non-human primates. Nat Commun. 2021;12(1):1253.
Goldberg E. The sperm-specific form of lactate dehydrogenase is required for fertility and is an attractive target for male contraception (a review). Biol Reprod. 2021;104(3):521-526.
Odet F, Duan C, Willis WD, et al. Expression of the gene for mouse lactate dehydrogenase C (Ldhc) is required for male fertility1. Biol Reprod. 2008;79(1):26-34.
Gruber FS, Johnston ZC, Barratt CL, Andrews PD. A phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity. Elife. 2020;9.
Baskin MJ. Temporary sterilization by the injection of human spermatozoa. A preliminary report. Am J Obstet Gynecol. 1932;24(6):892-897.
Naz RK. Antisperm contraceptive vaccines: where we are and where we are going? Am J Reprod Immunol. 2011;66(1):5-12.
O'Rand MG, Widgren EE, Wang Z, Richardson RT. Eppin: an effective target for male contraception. Mol Cell Endocrinol. 2006;250(1-2):157-162.
O'rand MG, Widgren EE, Sivashanmugam P, et al. Reversible immunocontraception in male monkeys immunized with eppin. Science. 2004;306(5699):1189-1190.
Mortazavi B, Allahyari Fard N, Karkhane AA, Shokrpoor S, Heidari F. Evaluation of multi-epitope recombinant protein as a candidate for a contraceptive vaccine. J Reprod Immunol. 2021;145:103325.
Page ST, Amory JK, Bremner WJ. Advances in male contraception. Endocr Rev. 2008;29(4):465-493.
Martin CW, Anderson RA, Cheng L, et al. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod Oxf Engl. 2000;15(3):637-645.
Roth MY, Shih G, Ilani N, et al. Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception. 2014;90(4):407-412.
Bole R, Lundy SD, Pei E, Bajic P, Parekh N, Vij SC. Rising vasectomy volume following reversal of federal protections for abortion rights in the United States. Int J Impot Res. 2023:1-4.
Glasier AF, Anakwe R, Everington D, et al. Would women trust their partners to use a male pill? Hum Reprod Oxf Engl. 2000;15(3):646-649.
Campelia GD, Abbe C, Nickels LM, McElmeel E, Amory JK. “Shared risk”: reframing risk analysis in the ethics of novel male contraceptives. Contraception. 2020;102(2):67-69.
2022 | Family Planning [Internet]. [cited May 29, 2023]. https://fphandbook.org/2022
Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum. Am J Obstet Gynecol. 2020;222(2):134-143.
Mancini I, Alvisi S, Gava G, Seracchioli R, Meriggiola MC. Contraception across transgender. Int J Impot Res. 2020;33(7):710-719.
Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982-2009. Glob Health Sci Pract. 2013;1(2):203-212.
Gaffikin L, Engelman R. Family planning as a contributor to environmental sustainability: weighing the evidence. Curr Opin Obstet Gynecol. 2018;30(6):425-431.
Townsend J, Sitruk-Ware R, RamaRao S, Sailer J. Contraceptive technologies for global health: ethically getting to safe, effective and acceptable options for women and men. Drug Deliv Transl Res. 2020;10(2):299-303.
Ensuring Human Rights in the Provision of Contraceptive Information and Services: Guidance and Recommendations [Internet]. Geneva: World Health Organization; 2014 [cited May 29, 2023]. (WHO Guidelines Approved by the Guidelines Review Committee). http://www.ncbi.nlm.nih.gov/books/NBK195054/